Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 62

1.

Galantamine effect on tularemia pathogenesis in a BALB/c mouse model.

Pohanka M, Pavlis O, Pikula J.

Iran Biomed J. 2012;16(3):156-61. doi: 10.6091/ibj.993.2012.

2.

Tularemia progression accompanied with oxidative stress and antioxidant alteration in spleen and liver of BALB/c mice.

Pohanka M, Pavlis O, Ruttkay-Nedecky B, Sochor J, Sobotka J, Pikula J, Adam V, Kizek R.

J Microbiol. 2012 Jun;50(3):401-8. doi: 10.1007/s12275-012-1621-8. Epub 2012 Jun 30.

PMID:
22752903
5.

Molecular immunology of experimental primary tularemia in mice infected by respiratory or intradermal routes with type A Francisella tularensis.

Conlan JW, Zhao X, Harris G, Shen H, Bolanowski M, Rietz C, Sjostedt A, Chen W.

Mol Immunol. 2008 May;45(10):2962-9. doi: 10.1016/j.molimm.2008.01.022. Epub 2008 Mar 5.

6.

Inhibition of Francisella tularensis LVS infection of macrophages results in a reduced inflammatory response: evaluation of a therapeutic strategy for intracellular bacteria.

D'Elia R, Jenner DC, Laws TR, Stokes MG, Jackson MC, Essex-Lopresti AE, Atkins HS.

FEMS Immunol Med Microbiol. 2011 Aug;62(3):348-61. doi: 10.1111/j.1574-695X.2011.00817.x. Epub 2011 Jun 16.

7.

Intranasal interleukin-12 treatment promotes antimicrobial clearance and survival in pulmonary Francisella tularensis subsp. novicida infection.

Pammit MA, Budhavarapu VN, Raulie EK, Klose KE, Teale JM, Arulanandam BP.

Antimicrob Agents Chemother. 2004 Dec;48(12):4513-9.

8.
9.

Specific antibodies protect gamma-irradiated mice against Francisella tularensis infection.

Kubelkova K, Krocova Z, Balonova L, Pejchal J, Stulik J, Macela A.

Microb Pathog. 2012 Nov-Dec;53(5-6):259-68. doi: 10.1016/j.micpath.2012.07.006. Epub 2012 Jul 25.

PMID:
22841607
10.

Survival of secondary lethal systemic Francisella LVS challenge depends largely on interferon gamma.

Elkins KL, Colombini SM, Meierovics AI, Chu MC, Chou AY, Cowley SC.

Microbes Infect. 2010 Jan;12(1):28-36. doi: 10.1016/j.micinf.2009.09.012. Epub 2009 Sep 23.

PMID:
19781659
11.

Assessment of antimicrobial peptide LL-37 as a post-exposure therapy to protect against respiratory tularemia in mice.

Flick-Smith HC, Fox MA, Hamblin KA, Richards MI, Jenner DC, Laws TR, Phelps AL, Taylor C, Harding SV, Ulaeto DO, Atkins HS.

Peptides. 2013 May;43:96-101. doi: 10.1016/j.peptides.2013.02.024. Epub 2013 Mar 14.

PMID:
23500517
12.

Francisella tularensis infection-derived monoclonal antibodies provide detection, protection, and therapy.

Savitt AG, Mena-Taboada P, Monsalve G, Benach JL.

Clin Vaccine Immunol. 2009 Mar;16(3):414-22. doi: 10.1128/CVI.00362-08. Epub 2009 Jan 28.

13.

Neisseria meningitidis PorB, a Toll-like receptor 2 ligand, improves the capacity of Francisella tularensis lipopolysaccharide to protect mice against experimental tularemia.

Chiavolini D, Weir S, Murphy JR, Wetzler LM.

Clin Vaccine Immunol. 2008 Sep;15(9):1322-9. doi: 10.1128/CVI.00125-08. Epub 2008 Jul 9.

14.

Early activation of NK cells after lung infection with the intracellular bacterium, Francisella tularensis LVS.

López MC, Duckett NS, Baron SD, Metzger DW.

Cell Immunol. 2004 Nov-Dec;232(1-2):75-85. Epub 2005 Mar 24.

PMID:
15922718
15.

Molecular immune responses to aerosol challenge with Francisella tularensis in mice inoculated with live vaccine candidates of varying efficacy.

Shen H, Harris G, Chen W, Sjostedt A, Ryden P, Conlan W.

PLoS One. 2010 Oct 12;5(10):e13349. doi: 10.1371/journal.pone.0013349.

17.

In vivo modulation of the murine immune response to Francisella tularensis LVS by administration of anticytokine antibodies.

Leiby DA, Fortier AH, Crawford RM, Schreiber RD, Nacy CA.

Infect Immun. 1992 Jan;60(1):84-9.

18.

Mucosal immunotherapy for protection from pneumonic infection with Francisella tularensis.

Troyer RM, Propst KL, Fairman J, Bosio CM, Dow SW.

Vaccine. 2009 Jul 16;27(33):4424-33. doi: 10.1016/j.vaccine.2009.05.041. Epub 2009 May 31.

19.

Nitric oxide-independent killing of Francisella tularensis by IFN-gamma-stimulated murine alveolar macrophages.

Polsinelli T, Meltzer MS, Fortier AH.

J Immunol. 1994 Aug 1;153(3):1238-45.

PMID:
8027551
20.

Consequences of delayed ciprofloxacin and doxycycline treatment regimens against Francisella tularensis airway infection.

Rotem S, Bar-Haim E, Cohen H, Elia U, Ber R, Shafferman A, Cohen O.

Antimicrob Agents Chemother. 2012 Oct;56(10):5406-8. doi: 10.1128/AAC.01104-12. Epub 2012 Jul 30.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk